Cited by 64Schizophrenia research and treatmentHallucinations in medical conditionsAdvanced MRI Techniques and Applications

Glutamate as a mediating transmitter for auditory hallucinations in schizophrenia: A 1H MRS study

Hugdahl, Kenneth, Craven, Alexander R., Nygård, Merethe, Løberg, Else-Marie, Berle, Jan Øystein, Johnsen, Erik, Kroken, Rune, Specht, Karsten +2 more·2015·Schizophrenia Research

Abstract

This is a (1)H MR spectroscopy (MRS) study of glutamate (Glu), measured as Glx, levels in temporal and frontal lobe regions in patients with schizophrenia compared with a healthy control group with the objective of revealing aspects of the underlying neurochemistry of auditory hallucinations. We further compared and correlated Glu(Glx) levels for the patients-only against frequency and severity of auditory hallucinations and the sum of Positive symptoms, and also for frequency and severity of emotional withdrawal, and sum of Negative symptoms. The sample included 23 patients with an ICD-10 and DSM-IV diagnosis of schizophrenia, and 26 healthy control subjects without any known psychiatric or neurological disorders. Symptom scores were obtained from the Positive and Negative Syndrome Scale (PANSS). (1)H MRS data were acquired on a 3T MR scanner from two temporal and two frontal voxels, using standard sequences and analysis parameters. The results showed that schizophrenia patients as a group had reduced Glu(Glx) levels in the voxels of interest compared to the healthy control subjects, while increased levels were found for patients with frequent and severe auditory hallucinations, relative to patients with less frequent and severe hallucination. We further found significant positive correlations between frequency and severity of auditory hallucinations, and for sum Positive symptoms, and Glu(Glx) levels in all regions, not seen when the analysis was done for negative symptoms. It is concluded that the results show for the first time that glutamate may be a mediating factor in auditory hallucinations in schizophrenia.

Integrity signals

Registry

Crossref · 10.1016/j.schres.2014.11.015

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Frontal-temporal Glx levels positively correlate with hallucination severity, but not with negative symptoms.

    “A significant positive correlation was also found between frontal-temporal Glx levels and hallucination severity (assessed with item P3 from the Positive and Negative Syndrome Scale, PANSS), while correlations with negative symptoms were close to zero.”
  • Hugdahl et al. demonstrated reduced Glx levels in the posterior temporal lobe and inferior frontal gyrus of schizophrenia participants relative to healthy controls.

    “Hugdahl et al 51 demonstrated reduced Glx levels (ie, the sum of Glu and Glutamine, Gln) in the posterior temporal lobe and the inferior frontal gyrus of SCZ participants relative to healthy controls.”

Cites

Flagged first, then by citations

2 of the 63 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Hugdahl, K., Craven, A. R., Nygård, M., Løberg, E.-M., Berle, J. Ø., Johnsen, E., Kroken, R., Specht, K., Andreassen, O. A., & Ersland, L.
Affiliations
  • Oslo University Hospital (NO)
  • University of Bergen (NO)
  • Haukeland University Hospital (NO)
Corresponding author
Hugdahl, Kenneth
Venue
Schizophrenia Research
Publisher
Elsevier BV
Published
2015-02
Volume
161
Issue
2-3
Pages
252-260
ISSN
0920-9964 (ISSN-L)
OpenAlex
W2155257635
Cited by
64
References
63
Citations by year
2026: 2 · 2025: 3 · 2024: 7 · 2023: 1 · 2022: 6 · 2021: 6 · 2020: 7 · 2019: 6 · 2018: 8 · 2017: 9 · 2016: 3 · 2015: 6
FWCI
4.58
Type
journal article
Language
en
Open access
closed
Locations
  • Schizophrenia Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • ERC (249516)
  • RCN FRIBIOMED (807698)
  • RCN (134088/320, 222373)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Hallucinations in medical conditions
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Advanced MRI Techniques and Applications
Keywords
glutamate
MeSH terms
Analysis of Variance, Brain, Brain Mapping, Female, Hallucinations, Humans, Male, Magnetic Resonance Spectroscopy, Protons, Psychiatric Status Rating Scales, Schizophrenia, Glutamic Acid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review